65,437 trials
Presbyopia
Primary: Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA — 60.5; 30.0; 45.2; 27.3 percentage of subjects with ≥ 15 letters
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo) — 16026; 5740; 19809 hours*ng/mL
Postmenopausal Osteoporosis
Primary: Cancellous Bone Formation Rate at Month 3 — 0.13; 0.01; 0.06 mm3/mm2/day
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 28; 20.1 total score on a scale
Prostate Cancer
Primary: Knowledge Assessed by Prostate Cancer Treatment Questionnaire — 0.69; 0.69; 0.64 score on a scale
Mydriasis · Dilation
Primary: Safety Measurements — 0.3; -0.2; 1.6; 0.0 score on a scale
Fabry Disease
Primary: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) — -2.514; -2.155 mL/min/1.73 m^2/year
Healthy Subjects (HS)
Primary: Number of Participants With Adverse Events (AEs) — 7 Participants
Acanthamoeba Keratitis
Primary: Clinical Resolution Rate — 84.8; 88.5 percentage of participants
Renal Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter
Diabetes · Myocardial Infarction · Stroke
Primary: First Occurrence of a Severe Cardiovascular Event — 403; 418 Participants — p=0.51
Health Knowledge, Attitudes, Practice · Health Risk Behaviors
Primary: Number of Early Infant Male Circumcision — 300 participants
Colorectal Cancer
Primary: Bowel Prep Efficacy - Boston Bowel Preparation Scale (BBPS) — 1.79; 2.33; 2.06; 2.45 score on a scale — p=<0.0001
Covid19
Primary: Time to Sustained Recovery in Days — 12; 13 days
Prostate Cancer
Primary: Failure-free Survival — 75.5; 63.0 Percentage of participants